Early identification of inflammatory mediators predicting fatal or inferior outcomes may prompt early treatment interventions, potentially yielding better outcomes in patients with severe COVID-19.2 In this study, we aimed to define the prognostic roles of HMGB1 and IL-6 in critically ill patients with COVID-19. This evidence concerns the gene HMGB1 and COVID-19.